Effect of caffeine on the anticonvulsant effects of oxcarbazepine, lamotrigine and tiagabine in a mouse model of generalized tonic-clonic seizures.
Journal Title: Pharmacological Reports - Year 2009, Vol 61, Issue 5
Abstract
Caffeine has been reported to be proconvulsant and to reduce the anticonvulsant efficacy of a variety of antiepileptic drugs (carbamazepine, phenobarbital, phenytoin, valproate and topiramate) in animal models of epilepsy and to increase seizure frequency in patients with epilepsy. Using the mouse maximal electroshock model, the present study was undertaken so as to ascertain whether caffeine affects the anticonvulsant efficacy of the new antiepileptic drugs lamotrigine, oxcarbazepine and tiagabine. The results indicate that neither acute nor chronic caffeine administration (up to 46.2 mg/kg) affected the ED(50) values of oxcarbazepine or lamotrigine against maximal electroshock. Similarly, caffeine did not modify the tiagabine electroconvulsive threshold. Furthermore, caffeine had no effect on oxcarbazepine, lamotrigine and tiagabine associated adverse effects such as impairment of motor coordination (measured by the chimney test) or long-term memory (measured by the passive avoidance task). Concurrent plasma concentration measurements revealed no significant effect on lamotrigine and oxcarbazepine concentrations. For tiagabine, however, chronic caffeine (4 mg/kg) administration was associated with an increase in tiagabine concentrations. In conclusion, caffeine did not impair the anticonvulsant effects of lamotrigine, oxcarbazepine, or tiagabine as assessed by electroconvulsions in mice. Also, caffeine was without effect upon the adverse potential of the studied antiepileptic drugs. Thus caffeine may not necessarily adversely affect the efficacy of all antiepileptic drugs and this is an important observation.
Authors and Affiliations
Magdalena Chrościńska-Krawczyk, Neville Ratnaraj, Philip Patsalos, Stanisław Czuczwar
Keywords
Related Articles
- EP ID EP91570
- DOI -
- Views 112
- Downloads 0
Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized by selective degeneration of dopaminergic neurons (DAergic) in the substantia nigra pars compacta (SNpc) and subsequent decrease i...
Glycoprotein (116 kD) isolated from Ulmus davidiana Nakai protects from injury of 12-O-tetradecanoylphorbol 13-acetate (TPA)-treated BNL CL.2 cells.
Ulmus davidiana Nakai (UDN) has been used for a long time to cure inflammation in oriental medicine. To evaluate the cytoprotective effects of the UDN glycoprotein, we measured cytotoxicity, the level of intracellular re...
Effects of midazolam and buspirone on in vivo concentration of amino acids and monoamine metabolites in the rat hippocampus.
The effects of anxiolytic doses of buspirone and midazolam (established in the conditioned fear test) on extracellular concentrations of glutamate, GABA, serotonin and dopamine metabolites in the hippocampus were examine...
Baclofen influences acquisition and MMP-2, MMP-9 levels in the hippocampus of rats after hypoxia.
Background: Baclofen, the agonist of GABA(B) receptors, influences hypoxia-induced deficits in learning and memory processes. Methods: We studied the effects of baclofen on acquisition in the passive avoidance test and i...
Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients.
The complex of serum amyloid A(SAA) and low-density lipoprotein (LDL), SAA-LDL, is considered a new and unique marker of oxidatively-modified LDL particles, which is associated with atherosclerotic conditions. This study...